Quantcast
Home > Quotes > FATE

Fate Therapeutics, Inc. Common Stock (FATE) Quote & Summary Data

FATE 
$18.37
*  
0.34
1.82%
Get FATE Alerts
*Delayed - data as of Mar. 18, 2019  -  Find a broker to begin trading FATE now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 19.11 / $ 18.10
Share Volume
599,736
50 Day Avg. Daily Volume
674,036
Previous Close
$ 18.71
52 Week High / Low
$ 19 / $ 8.3501
Market Cap
1,194,041,678
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
599,736
50 Day Avg. Daily Volume:
674,036

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.20

Trading Range

The current last sale of $18.37 is 120.00% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 19.11 $ 19
 Low: $ 18.10 $ 8.3501

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. We are developing first-in-class cell therapy product candidates based on a simple notion: we believe that better cell therapies start with better cells. To create better cell therapies, we use a therapeutic approach that we generally refer to as cell programming. For certain of our cell therapy product candidates, we use pharmacologic modulators, such as small molecules, to enhance the biological properties and therapeutic function of healthy donor cells ex vivo before our product candidates are administered to a patient. In other cases, we use human iPSCs to generate a clonal master iPSC line having preferred biological properties, and direct the fate of the clonal master iPSC line to create our cell therapy product candidate.  ... More ...  



Risk Grade

Where does FATE fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 18.71
Open Date:
Mar. 18, 2019
Close Price:
$ 18.37
Close Date:
Mar. 18, 2019


Consensus Recommendation

Analyst Info